This is a phase I,single center, randomized, double-blind and parallel group clinical trial .~The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous injections of QL1206 or Xgeva® in healthy volunteers.~The secondary objective are to assess the Clinical safety and immunogenicity similarity of single and subcutaneous injections of QL1206 or Xgeva® in healthy volunteers.~Meanwhile，observing the pharmacodynamic similarities of QL1206 or Xgeva® preliminarily.~Subjects would receive a single 120mg（1.7ml） of QL1206 or through subcutaneous injection.
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of QL1206 and Xgeva® in healthy adults.